Adaptive Phage Therapeutics, Inc.
The provided content indicates that the website aphage.com is currently experiencing server connection issues and is not accessible. No specific information about the company's mission, vision, products, services, or other details is available from the source.
Industries
Nr. of Employees
medium (51-250)
Adaptive Phage Therapeutics, Inc.
Products
BX004
A phage therapy for cystic fibrosis patients with chronic Pseudomonas aeruginosa respiratory infections, aimed at improving pulmonary function and reducing lung infections.
BX211
A personalized phage treatment for diabetic foot osteomyelitis associated with Staphylococcus aureus, designed to reduce the risk of amputation in diabetic patients.
Personalized Phage Treatment
Tailored phage therapies targeting specific bacterial strains in individual patients, developed within 6-8 weeks.
Optimized Phage Therapy
Phage therapies optimized for broad patient populations, targeting bacterial host range and resistance, developed within 1-2 years.
XMarker Platform
A metagenomics-based platform for discovering predictive microbial genomic signatures to develop biomarkers for diseases like IBD, liver disease, and colorectal cancer.
BX004
A phage therapy for cystic fibrosis patients with chronic Pseudomonas aeruginosa respiratory infections, aimed at improving pulmonary function and reducing lung infections.
BX211
A personalized phage treatment for diabetic foot osteomyelitis associated with Staphylococcus aureus, designed to reduce the risk of amputation in diabetic patients.
Personalized Phage Treatment
Tailored phage therapies targeting specific bacterial strains in individual patients, developed within 6-8 weeks.
Optimized Phage Therapy
Phage therapies optimized for broad patient populations, targeting bacterial host range and resistance, developed within 1-2 years.
XMarker Platform
A metagenomics-based platform for discovering predictive microbial genomic signatures to develop biomarkers for diseases like IBD, liver disease, and colorectal cancer.